Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline includes Lenzetto, Evamist, Testosterone Topical Solution, and others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,276.60 | 19.90 | -0.21% |
CAC 40 | 8,068.08 | 7.95 | 0.10% |
DAX 40 | 24,612.15 | 15.02 | 0.06% |
Dow JONES (US) | 46,601.78 | 1.20 | -0.00% |
FTSE 100 | 9,512.15 | 36.72 | -0.38% |
HKSE | 26,752.59 | 76.87 | -0.29% |
NASDAQ | 23,043.38 | 255.02 | 1.12% |
Nikkei 225 | 48,580.44 | 845.45 | 1.77% |
NZX 50 Index | 13,570.86 | 2.38 | 0.02% |
S&P 500 | 6,753.72 | 39.13 | 0.58% |
S&P/ASX 200 | 8,969.80 | 25.20 | -0.28% |
SSE Composite Index | 3,933.97 | 51.20 | 1.32% |